Idiopathic myelofibrosis: pathogenesis, natural history and management (Q41711774)

7 October 2017

1 reference

title

Idiopathic myelofibrosis: pathogenesis, natural history and management (English)

1 reference

7 October 2017

1 reference

Reilly JT

1

1 reference

7 October 2017

1 December 1997

1 reference

7 October 2017

1 reference

7 October 2017

11

1 reference

7 October 2017

4

1 reference

7 October 2017

233-242

1 reference

Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. Knochenmarksbefund

7 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Pathogenesis of idiopathic myelofibrosis: present status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Immunohistochemical and morphometric study including reactive (inflammatory) myelitis, secondary aplastic anemia, AIDS, myelodysplastic syndromes and primary (idiopa

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Raised urinary calmodulin levels in idiopathic myelofibrosis: possible implications for the aetiology of fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Structural characterization and biological functions of fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

FGF Mediation of Coronary Angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Anipulation of the Wound-Healing Process with Basic Fibroblast Growth Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Abnormalities of chromosome 13 in myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Molecular Definition of Interstitial Deletions of Chromosome 13 in Leukemic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Partial trisomy 1q in idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

A prognostic classification of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Anaemia in myelofibrosis: its value in prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Idiopathic myeloid metaplasia. Its evolution into acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Idiopathic myelofibrosis terminating in erythroleukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Development of acute leukaemia after idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Idiopathic myelofibrosis: anaemia may respond to low-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Reversal of myelofibrosis by hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

The effect of 1,25-dihydroxyvitamin D3 on the relationship between growth and differentiation in HL-60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

A role for 1,25-dihydroxyvitamin D3 in control of bone-marrow collagen deposition?

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Adverse effect of erythropoietin in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Suramin toxicity and efficacy in agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

Anagrelide: A New Drug for Treating Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990022-9

7 January 2021

10.1016/S0268-960X(97)90022-9

Identifiers

DOI

1 reference

7 October 2017

1 reference

PubMed ID

9481452